A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

Overview of attention for article published in Oncotarget, July 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 29 X posts from 20 X users, with an upper bound of 140,150 followers.

MEK inhibitor refametinib could be a better treatment strategy for some HER2-positive #breastcancer patients & should be tested in #clinicaltrials - new publication with @Dr_Alex_Eustace @sinead_toomey & other great Irish researchers #cancerresearc

RT @Naomi_Elster: Proud and happy that this #research I was involved with supported by @IrishCancerSoc @BREAST_PREDICT @RCSI_Irl on a poten…

RT @Naomi_Elster: Proud and happy that this #research I was involved with supported by @IrishCancerSoc @BREAST_PREDICT @RCSI_Irl on a poten…

RT @Naomi_Elster: Proud and happy that this #research I was involved with supported by @IrishCancerSoc @BREAST_PREDICT @RCSI_Irl on a poten…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 25 additional X posts.